Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio.
Vergori A, Tavelli A, Matusali G, Azzini AM, Augello M, Mazzotta V, Pellicanò GF, Costantini A, Cascio A, De Vito A, Marconi L, Righi E, Sartor A, Pinnetti C, Maggi F, Bai F, Lanini S, Piconi S, Levy Hara G, Marchetti G, Giannella M, Tacconelli E, d'Arminio Monforte A, Antinori A, Cozzi-Lepri A, On Behalf Of The Vax-Icona-Orchestra Study. Vergori A, et al. Vaccines (Basel). 2023 Oct 30;11(11):1664. doi: 10.3390/vaccines11111664. Vaccines (Basel). 2023. PMID: 38005996 Free PMC article.
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M; ICONA Study Group. Cozzi Lepri A, et al. AIDS. 2001 May 25;15(8):983-90. doi: 10.1097/00002030-200105250-00006. AIDS. 2001. PMID: 11399980 Clinical Trial.
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839
Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.
Solmone M, Girardi E, Lalle E, Abbate I, D'Arminio Monforte A, Cozzi-Lepri A, Alessandrini A, Piscopo R, Ebo F, Cosco L, Antonucci G, Ippolito G, Capobianchi MR; Hepal.Co.N.A. Study Group; I.Co.N.A Study Group. Solmone M, et al. Antivir Ther. 2006;11(1):87-94. Antivir Ther. 2006. PMID: 16518964
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group. Cicconi P, et al. HIV Med. 2010 Feb;11(2):104-13. doi: 10.1111/j.1468-1293.2009.00750.x. Epub 2009 Sep 1. HIV Med. 2010. PMID: 19732176 Free article.
362 results